Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMEN-LC03: SAR408701 vs Docetaxel in Previously Treated Metastatic NSCLC
NCT04154956Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2020
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoints: Progression-Free Survival up to 189 weeks and Overall Survival up to 189 weeks. Started Feb 2020; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04154956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154956.